InnovAge Holding Stock (NASDAQ:INNV), Trade Ideas

InnovAge Holding

InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.

Earnings

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

CGNT

INNV

MTRX

ORCL

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Matrix Service, Oracle And 3 Stocks To Watch Heading Into Tuesday

AAPL

QCOM

TSLA

The CNN Money Fear and Greed index showed further improvement in overall sentiment among U.S. investors on Monday.

U.S. stocks closed higher on Monday, with the Nasdaq adding more than 1% during the session ahead of the much-awaited inflation data due this week.

Investor Optimism Improves Further After Nasdaq Surges 1%

Intraday Update

Movers

ANGO

EOSE

NCMI

PFGC

U.S. stocks traded mixed, with the Dow Jones gaining close to 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

Performance Food Group, Stride, Progressive, H&amp;R Block And Other Big Stocks Moving Higher On Wednesday

InnovAge Holding Corp

InnovAge Revenue Ticks Up, But Challenges Remain

InnovAge GAAP EPS of -$0.03 in-line, revenue of $188.89M beats by $4.88M

InnovAge Holding Corp. (INNV) Q2 2024 Earnings Call Transcript

Goldman Sachs analyst Jamie Perse has maintained their neutral stance on INNV stock, giving a Hold rating on February 5. Geoff Meacham has given hi...

InnovAge Holding: A Cautious Hold Amidst Mixed Financial Signals

The latest announcement is out from InnovAge Holding (INNV). InnovAge Holding Corp. is set to engage investors with a live webcast on February 27, ...

InnovAge Holding Hosts Informative Investor Webcast Event

Analyst Jason Cassorla of Citi maintained a Hold rating on InnovAge Holding (INNV – Research Report), with a price target of $6.50. Jason Cassorla ...

InnovAge Holding: A Cautious Hold Amidst Growth Opportunity and Execution Hurdles

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The healthcare industry has historically provided significant returns to investors, with a predicted&nbsp;CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet. This is because many healthcare companies rely on trials that need to be approved by the Food and Drug Administration (<span>FDA</span>), making their performance difficult to predict.&nbsp;</p>



<p>Many companies, particularly small-cap companies, see massive share price declines when their trials fail or their treatments are not approved. Investors in the healthcare industry take great care as these risks make the industry a common target for short sellers. With that in mind, here are three <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> short sellers are prescribing for trouble that investors should sell.</p>



<h2>Healthcare Stocks Targeted by Short Sellers: Moderna (MRNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/04/mrna1600-300x169.png" alt="Moderna logo is seen at the entrance to its headquarters in Cambridge, Massachusetts. Moderna, Inc., (MRNA) is an American pharmaceutical and biotechnology company."><div>Source: Tada Images / Shutterstock.com</div></div><p><strong>Moderna </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mrna-stock-quote/"><strong>MRNA</strong></a>) is a pharmaceutical and biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on producing medicines based on mRNA, and its stock has surged drastically after receiving government approval for an mRNA vaccine for Covid-19 during the pandemic. </p>



<p>Moderna has experienced four days of consecutive losses after U.S. District Judge Mitchell Goldberg <a href="https://www.barrons.com/articles/moderna-stock-patent-covid-19-51638456764">ruled in favor</a> of <strong>Arbutus Biopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/abus-stock-quote/"><strong>ABUS</strong></a></span>), a biotech company that is involved in a patent infringement lawsuit with Moderna related to the latter&rsquo;s Covid-19 vaccines. Shares of Moderna fell 4% on Wednesday following an unfavorable ruling against the company.</p>



<p>Over <a href="https://www.investopedia.com/how-moderna-makes-money-5179565#:~:text=Moderna%20Revenue%20Breakdown%3A%20Product%20sales,Collaboration%20revenue%2C%20a%20tiny%20fraction.&amp;text=&#x2A;%20Sales%20of%20Moderna's%20COVID%2D19,sales%20in%20Q4%20FY%202021.">95% of Moderna&rsquo;s revenue</a> is generated through its product sales. Various grants and subsidies from the government and private organizations make up the remaining 5%. Despite Moderna&rsquo;s massive success in recent years due to its development of mRNA Covid-19 vaccines, the company&rsquo;s recent loss in the lawsuit will make it a vulnerable target for short sellers.</p>



<p>Furthermore, Moderna&rsquo;s financials raise concerns for investors. In the fourth quarter of the 2023 fiscal year, Moderna experienced a drop of <a href="https://investorplace.com/2024/03/its-time-3-failing-biotech-stocks-to-sell-right-now/">45% in total revenue</a> and an 85% fall in net income year-over-year. Moderna remains highly dependent on revenues from vaccines.  The company is also lacking experience in pharma sales compared to its larger competitors like <strong>Pfizer </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pfe-stock-quote/"><strong>PFE</strong></a>). Combined with the lawsuit loss, the company&rsquo;s prognosis is grim. Until the company can improve its declining revenue patterns and offload the heavy reliance on vaccine sales by expanding into multiple revenue streams, Moderna stock remains a sell.</p>



<h2>InnovAge (INNV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/innv1600-300x169.png" alt="InnovAge (INNV) offers comprehensive health care and support services to seniors. They strive to enable older adults to age independently at home."><div>Source: MacroEcon / Shutterstock.com</div></div><p><strong>InnovAge Holding Corp </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/innv-stock-quote/"><strong>INNV</strong></a>) is a healthcare company based in Denver, Colorado, that provides medical and ancillary services for the elderly who are in need of care and support to live independently. The firm operates in the <a href="https://www.medicare.gov/health-drug-plans/health-plans/your-coverage-options/other-medicare-health-plans/PACE">system known as PACE</a> (Program of All-Inclusive Care for the Elderly), and about 150 of these PACE programs currently serve more than 70,000 patients across the nation. </p>



<p>Recently, Goldman Sachs lowered its target price for InnovAge Holding from <a href="https://www.marketbeat.com/instant-alerts/nasdaq-innv-percent-advance-2024-04-01/">$8 to $7</a>, while JPMorgan Chase lowered its price target on shares from $7 to $6 in a research report published on Wednesday, March 13.</p>



<p>Moreover, the company&rsquo;s most recent reported balance sheet makes InnovAge a good target for short sellers. The company held <a href="https://simplywall.st/stocks/us/healthcare/nasdaq-innv/innovage-holding/news/innovage-holding-nasdaqinnv-has-debt-but-no-earnings-should">$123.1 million</a> in liabilities due within 12 months, along with an additional $108.2 million due after a year, while only holding $98.8 million in cash and $43.7 million worth of receivables. While its EPS has improved <a href="https://www.cnn.com/markets/stocks/INNV">64.82%</a> YoY, it remains negative at 0.03, and due to its overvaluation, investors should be cautious about InnovAge.</p>



<h2>Healthcare Stocks Targeted by Short Sellers: iBio (IBIO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div><p><strong>iBio</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ibio-stock-quote/"><strong>IBIO</strong></a>) is an American pharmaceutical company that focuses on biotherapeutic drugs. The producer&rsquo;s leading drug candidates of note include iBio-400, which is a vaccine that treats classical swine fever, and iBio-101, an immuno-oncology drug that treats cancer. </p>



<p>Yet, iBio is extremely far from a fully approved product that will generate a consistent profit. None of iBio&rsquo;s nine current drugs are currently in clinical trials, with most in the early discovery stage. The stock has <a href="https://finance.yahoo.com/quote/IBIO/">experienced a fall of 90%</a> in its price YoY, which may seem like a positive signal to buy. Although the company&rsquo;s net income in FY 2023 has improved from FY 2022, iBio is still losing money and is considered overvalued by several brokerages. Shares of iBio have fallen nearly 40% in the last five days, indicating it is getting heavily targeted by short sellers. </p>



<p>Furthermore, because iBio lacks an innovative drug that will enter the market in the next couple of years, its stock does not showcase any promising signs of performing well in the short or long term. Therefore, investors should consider selling IBIO stock.&nbsp;</p>



<p><strong><em>On Penny Stocks and Low-Volume Stocks:</em></strong><em>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em>&nbsp;</p>



<p><strong><em>Read More:</em></strong><em>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a>&nbsp;</p>



<p><em>On the date of publication, Andy Kim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Andy is a self-taught investor who is interested in ESG and socially responsible investing. He has managed the portfolio of a small investment fund and started his own research firm. Through his freelance writing on InvestorPlace, he hopes to find and share promising investments in companies with the goal of bettering the world.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/3-healthcare-stocks-short-sellers-are-prescribing-for-trouble/">3 Healthcare Stocks Short Sellers Are Prescribing for Trouble</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Healthcare Stocks Short Sellers Are Prescribing for Trouble

ABUS

IBIO

MRNA

Management

Press Releases

InnovAge Names Darlene Flaig as New Chief Nursing Officer

InnovAge to Announce Fiscal First Quarter 2024 Financial Results and Host Conference Call Tuesday, November 7, 2023

InnovAge Announces Financial Results For The Fiscal First Quarter Ended September 30, 2023

General

InnovAge Announces Acquisition of ConcertoCare's PACE Programs

InnovAge to Announce Fiscal Second Quarter 2024 Financial Results and Host Conference Call Tuesday, February 6, 2024

InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2023

Legal

SHAREHOLDER ALERT: Morris Kandinov Investigating BLNK, INNV, FNKO and AHCO; Shareholders are Encouraged to Contact the Firm

InnovAge to Host Investor Day on February 27, 2024

Health Care

InnovAge Launches First PACE Center in Florida Providing Comprehensive Healthcare Program for Seniors to Promote Independence

SHAREHOLDER ALERT: Morris Kandinov Investigating HRT, CRNC, SHC and INNV; Shareholders are Encouraged to Contact the Firm